Skip to contentN
Nutra Pharma Corp
N
NPHCNutra Pharma Corp Q4 2013 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$23.07K$23.07Kderived−85.5% vs Q4 2012 Net Income-$613.72K-$613.72KderivedN/M vs Q4 2012 EPS, diluted—
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Nutra Pharma Corp · CIK 1119643 · Engraved from SEC EDGAR
Not derived. Share counts vary by quarter.
Gross Profitderived$11,677−46.5% Operating Incomederived-$1,126,790N/M Operating Cash Flowderived-$114,413N/M Margins · derivedGross margin50.6%+36.9 pt vs Q4 2012
Operating margin-4884.4%−4020.5 pt vs Q4 2012
Net margin-2660.4%−1346.5 pt vs Q4 2012
ended Dec 31, 2013 · filed Mar 31, 2014 · 90 d after period end